TrialTargeted oncology2017

A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers.

Bernard Escudier et al.PubMed ↗Publisher ↗

No numbers read from the abstract.